RO5503781

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Neoplasms

Phase 1

A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia

CompletedNCT01462175

Hoffmann-La RocheNeoplasms

Start: 2011-11-30End: 2014-07-31Updated: 2016-11-02

A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

CompletedNCT01901172

Hoffmann-La RocheNeoplasms

Start: 2013-08-31End: 2015-06-30Updated: 2015-08-18

Related Papers

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.

2021-06-2829 citations

Contribution of Idasanutlin Exposure to Safety, Pharmacodynamics and Clinical Response of Patients with Acute Myeloid Leukemia Treated with Idasanutlin + Cytarabine in Phase I and III Studies

Blood2020-11-043 citations

Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.

Journal of Clinical Oncology2014-05-2066 citations